Impaired fibrinolysis in angiographically documented coronary artery disease. by Fernandes, Adriano Basques et al.
Research Article
Impaired Fibrinolysis in Angiographically Documented
Coronary Artery Disease
Adriano Basques Fernandes,1 Luciana Moreira Lima,1
Marinez Oliveira Sousa,1 Vicente de Paulo Coelho Toledo,1 Rashid Saeed Kazmi,2
Bashir Abdulgader Lwaleed,3 and Maria das Graças Carvalho1
1Faculty of Pharmacy, Federal University of Minas Gerais, Avenida Antonio Carlos 6627, 31270-901 Belo Horizonte, MG, Brazil
2Department of Haematology, University Hospital Southampton, Southampton, UK
3Faculty of Health Sciences, University of Southampton, Southampton, UK
Correspondence should be addressed to Rashid Saeed Kazmi; rashid.kazmi@uhs.nhs.uk
Received 13 October 2014; Revised 27 January 2015; Accepted 27 January 2015
Academic Editor: Owen McCarty
Copyright © 2015 Adriano Basques Fernandes et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Impaired fibrinolysismay predispose to coronary artery disease (CAD).Hypofibrinolysis due to high levels of plasminogen activator
inhibitor-1 (PAI-1) has been reported in CAD. A novel regulator of fibrinolytic activity, thrombin activatable fibrinolysis inhibitor
(TAFI), has attracted attention in recent years. It acts by blocking the formation of a ternary complex of plasminogen, fibrin, and
tissue plasminogen activator (t-PA). Previously ambiguous results regarding TAFI levels have been reported in CAD.Wemeasured
plasma levels of PAI-1 and TAFI antigen in 123 patients with age ranging from 40 to 65 years who had been submitted to coronary
angiography and assessed the association of thesemarkerswith the extent of stenosis in three groups: angiographically normal artery
(NAn), mild to moderate atheromatosis (MA), and severe atheromatosis (SA). Plasma levels of PAI-1 were increased in patients
with severe atheromatosis compared to mild/moderate atheromatosis or to normal patients (66.60, 40.50, and 34.90 ng/mL, resp.;
P < 0.001). For TAFI no difference was found between different groups. When patients were grouped in only two groups based
on clinical cut-off point for intervention (stenosis less than or above 70%) we found increased plasma levels for PAI-1 (37.55 and
66.60 ng/mL, resp.; P < 0.001) and decreased plasma levels for TAFI (5.20 and 4.53 𝜇g/mL, resp.; P = 0.04) in patients with stenosis
above 70%. No difference was found in PAI-1 or TAFI levels comparing the number of affected vessels. Conclusion. As evidenced
by a raised level of PAI-1 antigen, one can suggest an impaired fibrinolysis in stable CAD, although no correlation with the number
of affected vessels was found. Curiously, a decreased plasma level of total TAFI levels was observed in patients with stenosis above
70%. Further studies measuring functional TAFI are required in order to elucidate its association with the extent of degree of
atheromatosis.
1. Introduction
The endothelium mediates a variety of vital physiological
functions. While in health it maintains vascular integrity by
expressing vasoprotective and thromboresistant molecules,
on activation endothelial cells (ECs) acquire a phenotype
that promotes atherosclerosis [1]. The thrombin catalyzed
conversion of plasma fibrinogen into fibrin is the final step
of coagulation cascade during haemostasis. The formation of
thrombus is followed by the process of fibrinolysis which con-
sists of an enzymatic dissolution of the fibrin clot by plasmin.
It is controlled by endothelial cells through secretion of phys-
iological plasminogen activators like tissue type plasminogen
activator (t-PA) and urokinase type plasminogen activator
(u-PA). Fibrinolysis is initiated when both plasminogen
and t-PA bind to fibrin surface to generate plasmin [2].
However, plasmin is generated on the surface of endothelial
cells in the presence or absence of fibrin. In the absence of
fibrin plasmin generation is dependent on the constitutively
expressed plasminogen and t-PA receptor, annexin 2A. The
endothelium also exerts an inhibitory effect on fibrinolysis
through the synthesis of an inhibitor, type 1 plasminogen
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activator inhibitor (PAI-1). High levels of PAI-1 have been
shown to be associated with CAD [3, 4]. Yet another fibri-
nolytic inhibitor is thrombin activatable fibrinolysis inhibitor
(TAFI), a plasma zymogen that potently inhibits fibrinolysis
when converted to an active enzyme by thrombin, plasmin,
trypsin, and, more efficiently, thrombin-thrombomodulin
complex [5]. Activated TAFI (TAFIa) inhibits fibrinolysis by
removing the carboxyterminal lysine (and arginine) residues
on partially degraded fibrin, blocking the formation of a
ternary complex of plasminogen, and t-PA. Some studies have
shown a trend for increased TAFI levels in CAD patients [6–
8]. On the contrary other investigators have found decreased
levels of TAFI in CAD patients [9].
The aim of this study was to investigate the association
of PAI-1 and TAFI antigen levels with increasing degrees of
coronary atheromatosis in patients undergoing angiography.
2. Material and Methods
Thepopulation investigated consisted of 123 subjects with age
ranging from 40 to 65 years, who had been consecutively
submitted to coronary angiography in the Department of
Haemodynamics of Socor Hospital, Belo Horizonte, Brazil.
This protocol was submitted to the local ethical committees
in research of SocorHospital and Federal University ofMinas
Gerais. Signed informed consent was required for all subjects
enrolled in this study.
This study assessed a population of intermediate to high
risk of CAD who had been referred for catheterization due
to worsening clinical features on a background of a history of
stable angina. Patients with acute coronary syndrome in the
preceding 3 months were excluded from the study as were
those having concomitant treatment with anticoagulants,
lipid lowering drugs, or estrogens, patients with known
bleeding or thrombotic disorders, and those with renal,
hepatic, autoimmune, or malignant diseases.
Coronary angiography was performed in all 123 subjects
by percutaneous transfemoral approach. The images were
recorded digitally and all angiograms were analyzed by
three experienced cardiologists. The patients were grouped
according to the angiographic findings as follows: no stenosis
(Group I), stenosis of up to 30% of the luminal diameter in at
least one coronary artery (Group II), stenosis of 30 to 70% of
the luminal diameter in at least one coronary artery (Group
III), and stenosis of more than 70% of the luminal diameter
in at least one coronary artery (Group IV).
Blood samples were collected from 12 h fasting patients
after coronary angiography (since patients stratification was
dependent on this procedure), however, before any other
intervention following angiography, into vacuum tubes con-
taining 3.2 w/v sodium citrate as anticoagulant. Blood sam-
ples were immediately centrifuged at 2100 g for 20 minutes
and plasma samples were separated and stored at −70∘C until
analysis.
Plasma level of TAFI was performed using a com-
mercially available ELISA Kit (TAFI Antigen Kit, Affinity
Biologicals Inc., Canada) according to the manufacturer’s
instructions.
Quantitative determination of plasma TAFI was per-
formed using citrated set diagnostic Visualize TAFI Anti-
gen Kit (Affinity Biologicals Inc., Canada) whose analytical
principle is the enzyme-linked immunosorbent assay (ELISA
capture), strictly following the instructions provided by the
manufacturer. A microplate reader, BIO-RAD 550-USA, was
used for reading the reaction. The reference curve was
performed using the standard provided by the manufac-
turer obtaining the points of 6.8, 3.4, 1.7, 0.850, 0.425, and
0.213mg/mL and two plasma controls provided by the kit
were used to verify the assay performance.The concentration
of TAFI in the sample was obtained using the following
equation:
log (𝑦) = 𝐴 + 𝐵𝑥 log (𝑥) , (1)
with reference value from 5.8 to 10.0 𝜇g/mL.
PAI-1 level was determined using a commercial ELISA
Kit (IMUBIND PAI-1 ELISA Kit, American Diagnostica Inc.,
USA). The intra- and interassay coefficients were 9.0% and
6.6%, respectively (IMUBIND PAI-1 ELISA Kit, American
Diagnostica Inc., USA). For both, TAFI and PAI-1, control
plasmas were used to verify the assay performance.
Normal distribution of the data was checked by Shapiro-
Wilks test. The results were presented as mean and standard
deviation (SD) when normally distributed and otherwise as
median and interquartile ranges (25th and 75th percentiles).
For normally distributed data, ANOVA was used to com-
pare three groups. Mann-Whitney and Kruskal-Wallis tests
followed by Dunn’s test were used in case of non-normally
data for comparison of three groups. Statistical analysis was
performed by Sigma Stat version 1.0 software system. A value
of 𝑃 < 0.05 was chosen for statistical significance.
3. Results
The baseline characteristics of the study participants are
presented in Table 1. The three groups showed homogeneity
in relation to age, sex, and body mass index and no sta-
tistically significant difference was noted. The incidence for
hypertension was high in all three groups. The differences in
the incidence of smoking, sedentary lifestyle, and previous
history of CADwere statistically significant amongst different
degrees of severity of CAD.
Plasma levels of PAI-1 were increased in patients
with severe atheromatosis (Group IV) compared to
mild/moderate atheromatosis (Groups II/III) (𝑃 < 0.001) or
to angiographically normal (Group I) patients. For TAFI no
statistically significant difference was found between groups.
Plasma levels of PAI-1 and TAFI are presented in Table 2.
Considering that a clinical intervention must be made in
all patients presenting with stenosis above 70%, all of them
were rescored in two groups: stenosis of up to 70% of the
luminal diameter in at least one coronary artery and stenosis
of more than 70% of the luminal diameter in at least one
coronary artery. Table 3 shows results for PAI-1 and TAFI in
these two groups.
Based on this clinical cut point for intervention, we found
increased plasma levels for PAI-1 (𝑃 < 0.001) and decreased
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Table 1: Baseline patients’ characteristics.
Group I Groups II/III Group IV 𝑃
𝑛 (M/F) 35 (16/19) 31 (17/14) 57 (31/26) ns
Men 16 (45.7%) 17 (54.8%) 31 (54.4%) ns
Age (years) 59.0 ± 7.5 59.5 ± 9.0 60.5 ± 8.8 ns
BMI (Kg/m2) 25.3 ± 4.1 26.8 ± 4.7 25.8 ± 3.5 ns
Current smoker 6 (17.1%) 8 (25.8%) 23 (40.4%)a 𝑃a = 0.020
Hypertension 31 (88.6%) 25 (80.6%) 48 (84.2%) ns
Sedentary lifestyle 33 (94.3%) 23 (74.2%)A 43 (75.4%)a 𝑃
a
= 0.021
𝑃
A
= 0.023
Family history of CAD 14 (40.0%) 18 (58.1%) 29 (50.8%) ns
Diabetes mellitus 5 (14.3%) 7 (22.6%) 8 (14.0%) ns
Previous history of CAD 7 (20.0%) 12 (38.7%) 35 (61.4%)a 𝑃a < 0.0001
𝑛 = sample size; M = male; F = female; BMI = body mass index; ns = not significant; Group I = normal; Groups II/III = mild/moderate atheromatosis, up to
70% in at least one coronary artery; Group IV = severe atheromatosis, >70% in at least one coronary artery; a/A = significant difference to Group I (ANOVA).
Table 2: Plasma fibrinolytic markers.
Group I Groups II/III Group IV 𝑃
𝑛 35 31 57 —
PAI-1 34.90 (27.86; 42.43) 40.50 (34.24; 51.83) 66.60a,b (44.70; 91.65) 𝑃 < 0.001
TAFI 5.71 ± 1.73 5.21 ± 1.42 4.97 ± 1.41 ns
𝑛 = sample size; Group I = normal; Groups II/III = mild/moderate atheromatosis, up to 70% in at least one coronary artery; Group IV = severe atheromatosis,
>70% in at least one coronary artery; PAI-1 = type 1 plasminogen activator inhibitor; TAFI = thrombin activatable fibrinolysis inhibitor; aversus Group I and
bversus Groups II/III; ns = not significant.
Values for PAI-1 are given in median (25th and 75th percentiles) and expressed in (ng/mL).
Values for TAFI are given in mean ± SD and expressed in (𝜇g/mL).
Table 3: Plasma fibrinolysis markers considering stenosis of 70% as
clinical cut point for intervention.
Stenosis < 70% Stenosis > 70% 𝑃
𝑛 66 57 —
PAI-1 37.55 (30.90; 49.20) 66.60a (44.70; 91.65) 𝑃 < 0.001
TAFI 5.20 (4.37; 6.31) 4.53a (4.04; 5.63) 𝑃 = 0.04
𝑛 = sample size; PAI-1 = type 1 plasminogen activator inhibitor; TAFI =
thrombin activatable fibrinolytic inhibitor; aversus stenosis <70%. Values
for PAI-1 and TAFI are given in median (25th and 75th percentiles) and
expressed in ng/mL and 𝜇g/mL, respectively.
plasma levels for TAFI (𝑃 = 0.04) in patients with stenosis of
more than 70%.
We also explored the severity of CAD through the num-
ber of affected vessels in patients with stenosis of more than
70% versus plasma levels of PAI-1 and TAFI. No statistically
significant difference was found between groups (Table 4).
4. Discussion
Regulation of blood coagulation is an intricate coordination
between different pathways. Maintaining a balance between
thrombin-stimulated fibrin clot formation and plasmin-
induced clot lysis is essential for optimal haemostasis. Any
disturbance in these pathways causes a haemorrhagic or a
Table 4: Plasma fibrinolysis markers considering number of
affected vessels.
1v 2v 3v 𝑃
𝑛 16 13 28 —
PAI-1 92.79 ± 60.45 71.83 ± 39.29 62.15 ± 31.97 ns
TAFI 5.31 ± 1.52 4.75 ± 1.16 4.87 ± 1.46 ns
𝑛 = sample size; 1v = stenosis in one vessel; 2v = stenosis in two vessels; 3v
= stenosis in three or more vessels; PAI-1 = type 1 plasminogen activator
inhibitor; TAFI = thrombin activatable fibrinolytic inhibitor; ns = not
significant. Values for PAI-1 and TAFI are given in mean ± SD and expressed
in ng/mL and 𝜇g/mL, respectively.
thrombotic tendency depending on the shift of the balance
[10]. The data from this study demonstrate that fibrinolysis
is impaired in subjects with angiographically documented
CAD. PAI-1 levels were increased in patients with severe
atheromatosis compared to mild/moderate atheromatosis
(𝑃 < 0.001) or angiographically normal patients.
Increased levels of PAI-1 have been described in patients
with CAD after myocardial infarction (MI) [3] and are
considered a risk factor for recurrence [4]. We tried to
correlate the severity of disease with the number of affected
vessels and PAI-1 levels, but no significant difference between
different groups was found (Table 4). Thrombin also plays an
important role in fibrinolytic modulation through activation
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of TAFI [11]. Activated TAFI inhibits plasmin formation and
downregulates fibrinolysis [5] contributing to a hypofibri-
nolytic state in cardiovascular disease [9]. In the present
study, we did not find any significant difference in TAFI levels
between groups (Table 2). Interestingly, when we rescored
groups based on clinical cut point for intervention (stenosis
of more than 70%) TAFI plasma levels were decreased in
subjects with stenosis of more than 70% (Table 3) compared
to those with stenosis of up to 70%, consistent with a
previous study [9]. No difference was found between severity
of disease through number of affected vessels and TAFI
levels (Table 4). Controversial results regarding TAFI levels in
CAD patients have been described possibly because of both
different characteristics of patients investigated and methods
used for its determination [12].
Different clinical studies have investigated the possible
relationship between TAFI and cardiovascular events [12].
The results have been inconsistent and studies have reported
high, normal, and low plasma levels of TAFI [6–8].
We could speculate that the amount of TAFI generated
during coagulation and fibrinolysis varies in different car-
diovascular disease stages and, in addition, different results
obtained through different assays demonstrate the variable
reactivity of antibodies toward different isoforms of TAFI.
An important study [13] comparing different TAFI assays
has demonstrated that pro-TAFI assay measures high levels
of TAFI in CAD, while TAFI antigen assays can detect no
alterations in TAFI plasma levels or a slight decrease of TAFI
plasma levels in the same samples. We can also speculate
that different antibodies react to different isoforms of TAFI,
yielding ambiguous results.
The importance of haemostatic alterations in CAD is
being increasingly recognised in cardiovascular diseases. Our
study has demonstrated that PAI-1 plasma levels are increased
in a limited number of CAD patients in Brazilian patients,
in line with previous studies [5, 9]. Although decreased TAFI
levels are in agreementwith other studies [9], its physiological
relevance and pathogenic role remain unclear since only
the levels of TAFI antigen were evaluated precluding any
conclusion on the TAFI function.
The major limitation of the present study was that our
observationswere based on a small number of patients, which
precludes a specific cut-off for PAI-1 and TAFI antigens in
severe disease. Another limitation is the fact that in a cohort
cross-sectional study we tried to evaluate associations, not
predictions or causation. Finally, our findings are related to a
group of patients referred for catheterization due to thoracic
pain selected by experienced cardiologists.Thus, our subjects
with no stenosis may not be representative of the general
population. Further work is required to investigate PAI-1 and
TAFI antigens roles in CAD in a greater number of patients
and functional assays are also required for clarifying the real
role of these fibrinolysis inhibitors. Also known modifiers of
PAI-1 levels such as smoking, bodymass index, and circadian
variation should be considered for result interpretation.
In conclusion, this small study confirms an impaired
fibrinolysis in stable CAD considering the increased levels of
PAI-I, indicating that this marker is actually associated with
the atheromatosis extent, although the number of affected
vessels seems not to have contributed to increase of PAI-1
levels.
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